advertisement
Abstract #19142 Published in IGR 3-1
Update on topical carbonic anhydrase inhibitors
Herkel U; Pfeiffer NCurrent Opinions in Ophthalmology 2001; 12: 88-93
Topical carbonic anhydrase inhibitors are a novel addition to the armamentarium of medical glaucoma treatment; dorzolamide has been available since 1995, and brinzolamide since 1998. They lower intraocular pressure by inhibiting carbonic anhydrase, a key enzyme for aqueous humor formation. Intraocular pressure-lowering activity of the substances appears to be the same and is similar to that of most other agents, but it does not reach the activity of the unselective beta-blocker timolol or the prostaglandin latanoprost. On concomitant treatment, additivity is reached with all other topical agents. A possible improvement of blood flow may offer an additional benefit, but its significance for the long-term outcome for human glaucoma remains to be shown. Side-effects are mostly local. A more physiological pH of brinzolamide appears to be advantageous.
Dr U Herkel, Mainz University Hospital, Mainz, Germany
Classification:
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
